XPO $1.28 billion senior notes offerings
The senior notes are due 2028 and 2031
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
InflaRx follow-on offering
The shares are listed on the Nasdaq Global Market
Ormat Technologies $297 million follow-on offering
The stock is listed on the NYSE and Tel Aviv Stock Exchange
Alteryx $450 million senior notes offering
The 8.75% notes are due 2028
Stanley Black & Decker $750 million notes offering
The investment-grade notes are due 2026 and 2028
Eli Lilly $4 billion notes offering
The investment-grade notes are due 2026, 2033, 2053 and 2063
ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering